Identification of the immunodominant CTL epitope of EGFP in C57BL/6 mice

Gene Therapy

Volumn 15, Issue 9, 2008, Pages 700-701

  Han, W G H ^a   Unger, W W J ^a   Wauben, M H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; T LYMPHOCYTE ANTIGEN;

ANTIGEN RECOGNITION; C57BL 6 MOUSE; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LETTER; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TRANSGENE;

ANIMALS; GENE THERAPY; GREEN FLUORESCENT PROTEINS; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 42149156556     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303104     Document Type: Letter

References (10)

1. Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M et al Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951-1959.
2. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: Implications for gene therapy. Gene Ther 1999; 6: 1305-1312.
3. Andersson G, Illigens BM, Johnson KW, Calderhead D, LeGuern C, Benichou G et al. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 2003; 101: 4305-4312.
4. Annoni A, Battaglia M, Follenzi A, Lombardo A, Sergi-Sergi L, Naldini L et al. The immune response to lentiviral-delivered transgene is modulated in vivo by transgene expressing antigen presenting cells but not by CD4+CD25+ regulatory T cells. Blood 2007; 110: 1788-1796.
5. Andersson G, Denaro M, Johnson K, Morgan P, Sullivan A, Houser S et al. Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. Mol Ther 2003; 8: 385-391.
6. Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, Tüting T et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: Identification of an H2-Kd-restricted CTL epitope. Gene Ther 2000; 7: 2036-2040.
7. Skelton D, Satake N, Kohn DB. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther 2001; 8: 1813-1814.
8. Denaro M, Oldmixon B, Patience C, Andersson G, Down J. EGFP-transduced EL-4 cells from tumors in C57BL/6 mice. Gene Ther 2001; 8: 1814-1815.
9. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-175.
10. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.